Reference : Impact thérapeutique du dépistage de l’ischémie myocardique silencieuse chez le sujet...
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
Human health sciences : Endocrinology, metabolism & nutrition
Impact thérapeutique du dépistage de l’ischémie myocardique silencieuse chez le sujet diabétique de type 2
[en] Therapeutic impact of screening for myocardial ischemia among asymptomatic type 2 diabetic subjects
Wallemacq, Caroline [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Revue Médicale Suisse
Yes (verified by ORBi)
[en] Diabetes Mellitus, Type 2/complications ; Humans ; Mass Screening ; Myocardial Ischemia/complications/diagnosis
[en] Coronary artery disease is the major cause of mortality of type 2 diabetic subjects. Its early diagnosis to prevent progression and clinical events has intuitive appeal. Somehow, rationale for screening has not been clearly established. Screening should not modify the medical therapy because diabetic subjects have to be treated in a secondary prevention strategy. We have no data from randomized trials concerning a better outcome after revascularization in this specific population. The question how to select the high risk population to be screened has no response by now. SPECT and stress echocardiography seem valuable for screening but not for risk stratification. A large randomized clinical trial is required to confirm the cost-utility ratio of such a screening.
Researchers ; Professionals ; Students
Tous nos remerciements à Médecine et Hygienne

File(s) associated to this reference

Fulltext file(s):

Open access
impact thérapeutique du dépistage.pdfAuthor postprint184.28 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.